Exposure to atropinic drugs and frailty status

Journal of the American Medical Directors Association

Volumn 16, Issue 3, 2015, Pages 253-257

  Moulis, Florence ^a,b,c,d   Moulis, Guillaume ^a,b,c   Balardy, Laurent ^c   Gérard, Stéphane ^a,b,c   Montastruc, François ^a,b,c   Sourdet, Sandrine ^a,b,c   Rougé Bugat, Marie Eve ^a,b,c,d   Lapeyre Mestre, Maryse ^a,b,c   Montastruc, Jean Louis ^a,b,c   Rolland, Yves ^a,b,c   Vellas, Bruno ^a,b,c  

^a Faculté de Médecine Centre Hospitalo universitaire   (France)

^b INSERM   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d Département Universitaire de Médecine Générale   (France)

Author keywords

Anticholinergic drug; Atropinic burden; Frailty

Indexed keywords

CAPTOPRIL; CHOLINERGIC RECEPTOR BLOCKING AGENT; FUROSEMIDE; PREDNISOLONE;

AGED; ANTICHOLINERGIC DRUG SCALE; ARTICLE; ATROPINIC BURDEN SCORE; CHARLSON COMORBIDITY INDEX; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DRUG EXPOSURE; FEMALE; FRAIL ELDERLY; FRANCE; FUNCTIONAL STATUS; GENERAL HEALTH STATUS ASSESSMENT; GERIATRIC HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRESCRIPTION; SCORING SYSTEM; VERY ELDERLY; AGE; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG UTILIZATION; GERIATRIC ASSESSMENT; MULTIVARIATE ANALYSIS; NEEDS ASSESSMENT; NONPARAMETRIC TEST; PROCEDURES; RISK ASSESSMENT; STATISTICAL MODEL; UNIVERSITY HOSPITAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; FEMALE; FRAIL ELDERLY; FRANCE; GERIATRIC ASSESSMENT; HOSPITALS, UNIVERSITY; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; NEEDS ASSESSMENT; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC;

EID: 84924255636     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2014.11.017     Document Type: Article

References (31)

1. Clegg A., Young J., Iliffe S., et al. Frailty in elderly people. Lancet 2013, 381:752-762.
2. Morley J.E., Vellas B., van Kan G.A., et al. Frailty consensus: A call to action. JAm Med Dir Assoc 2013, 14:392-397.
3. Morley J.E. Frailty: Diagnosis and management. JNutr Health Aging 2011, 15:667-670.
4. Morley J.E. Frailty screening comes of age. JNutr Health Aging 2014, 18:453-454.
5. Wilson N.M., Hilmer S.N., March L.M., et al. Associations between drug burden index and falls in older people in residential aged care. JAm Geriatr Soc 2011, 59:875-880.
6. Landi F., Dell'Aquila G., Collamati A., et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. JAm Med Dir Assoc 2014, 15:825-829.
7. Moga D.C., Carnahan R.M., Lund B.C., et al. Risks and benefits of bladder antimuscarinics among elderly residents of Veterans Affairs Community. JAm Med Dir Assoc 2013, 14:749-760.
8. Fox C., Richardson K., Maidment I.D., et al. Anticholinergic medication use and cognitive impairment in the older population: The Medical Research Council cognitive function and ageing study. JAm Geriatr Soc 2011, 59:1477-1483.
9. Cruz-Oliver D.M., Malmstrom T.K., Roegner M., et al. Cognitive deficit reversal as shown by changes in the Veterans Affairs Saint Louis University Mental Status (SLUMS) examination scores 7.5 years later. JAm Med Dir Assoc 2014, 15:687.e5-687.e10.
10. Morley J.E. Anticholinergic medications and cognition. JAm Med Dir Assoc 2011, 12:543-543.e1.
11. Lowry E., Woodman R.J., Soiza R.L., Mangoni A.A. Associations between the anticholinergic risk scale score and physical function: Potential implications for adverse outcomes in older hospitalized patients. JAm Med Dir Assoc 2011, 12:565-572.
12. American Geriatrics Society 2012 Beers Criteria Update Expert Panel American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. JAm Geriatr Soc 2012, 60:616-631.
13. Laroche M.-L., Charmes J.-P., Merle L. Potentially inappropriate medications in the elderly: A French consensus panel list. Eur J Clin Pharmacol 2007, 63:725-731.
14. Montastruc F., Retailleau E., Rousseau V., et al. Atropinic burden of prescription forms in France: A study in community pharmacies in 2013. Eur J Clin Pharmacol 2014, 70:1147-1148.
15. Montastruc F., Gardette V., Cantet C., et al. Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: Be aware ofatropinic and benzodiazepine drugs!. Eur J Clin Pharmacol 2013, 69:1589-1597.
16. Montastruc F., Duguet C., Rousseau V., et al. Potentially inappropriate medications and adverse drug reactions in the elderly: A study in a PharmacoVigilance database. Eur J Clin Pharmacol 2014, 70:1123-1127.
17. Tavassoli N., Guyonnet S., Abellan Van Kan G., et al. Description of 1,108 older patients referred by their physician to the "Geriatric Frailty Clinic (G.F.C) for Assessment of Frailty and Prevention of Disability" at the Gerontopole. JNutr Health Aging 2014, 18:457-464.
18. Fried L.P., Tangen C.M., Walston J., et al. Frailty in older adults: Evidence for a phenotype. JGerontol A Biol Sci Med Sci 2001, 56:M146-M156.
19. Carnahan R.M., Lund B.C., Perry P.J., et al. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: Associations with serum anticholinergic activity. JClin Pharmacol 2006, 46:1481-1486.
20. Montastruc J.-L., Durrieu G., Sommet A., et al. Anticholinergics, antimuscarinics or atropinics? About the words in pharmacology. Br J Clin Pharmacol 2010, 69:561-562.
21. Durán C.E., Azermai M., Vander Stichele R.H. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol 2013, 69:1485-1496.
22. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. Anew method of classifying prognostic comorbidity in longitudinal studies: Development and validation. JChronic Dis 1987, 40:373-383.
23. Moulis F., Moulis G., Balardy L., et al. Searching for a polypharmacy threshold associated with frailty. JAm Med Dir Assoc 2015, 16. (Letter-Editor in press).
24. Kelaiditi E., Cesari M., Canevelli M., et al. Cognitive frailty: Rational and definition from an (I.A.N.A./I.A.G.G.) international consensus group. JNutr Health Aging 2013, 17:726-734.
25. Malmstrom T.K., Morley J.E. The frail brain. JAm Med Dir Assoc 2013, 14:453-455.
26. Shimada H., Makizako H., Doi T., et al. Combined prevalence of frailty and mild cognitive impairment in a population of elderly Japanese people. JAm Med Dir Assoc 2013, 14:518-524.
27. Rudolph J.L., Salow M.J., Angelini M.C., McGlinchey R.E. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008, 168:508-513.
28. Mebarki S., Trivalle C. Echelles d'évaluation de l'effet anticholinergique des médicaments. Neurologie-Psychiatrie-Gériatrie 2012, 12:131-138.
29. Boustani M.A., Campbell N., Munger S., et al. Impact of anticholinergics on the aging brain: A review and practical application. Aging Health 2008, 4:311-320.
30. Santos-Eggimann B., Cuénoud P., Spagnoli J., Junod J. Prevalence of frailty in middle-aged and older community-dwelling Europeans living in 10 countries. JGerontol A Biol Sci Med Sci 2009, 64:675-681.
31. Montastruc J.-L., Montastruc F. Prescribe, but also know how to "deprescribe". Prescrire Int 2013, 22:192.